Als nächstes

Pancreatic Cancer Pill Marks Major Breakthrough

173 Ansichten· 11/20/26
Picup ENG
Picup ENG
Abonnenten
0

A new pill, daraxonrasib, is being hailed by experts as the biggest breakthrough in pancreatic cancer treatment in decades. According to early clinical trial results, the drug, when combined with chemotherapy, halted tumour growth in nearly all of the 61 patients with advanced pancreatic cancer. Tumours shrank or disappeared in just over 60 percent of those treated, and in one in twelve patients the cancer became undetectable on CT scans. While the results have sparked significant hope among the medical community, experts and organisations such as Cancer Research UK emphasise that these are early findings and further research is required to determine the long-term impact and effectiveness in larger groups. Daraxonrasib is a KRAS inhibitor already approved in the United States, targeting mutations common in pancreatic cancer. The development has been welcomed as a substantial advance for patients with one of the deadliest forms of cancer, but doctors caution that it is not yet a cure.

Zeig mehr

 0 Bemerkungen sort   Sortiere nach


Als nächstes